- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07588633
Fiber Nutritional Supplement for Management of Constipation During Pregnancy
Effectiveness of Daily Supplementation of a Fiber Nutritional Supplement (Materna® Opti-fiber) and Counselling for Constipation Management in Pregnancy
This study aims to evaluate the effectiveness of a daily Fiber Nutritional Supplement (Materna® Opti fiber), containing partially hydrolyzed guar gum (PHGG) and vitamins C, D, zinc, and selenium, combined with nutritional counselling, for the management of constipation during pregnancy. Constipation is a common gastrointestinal complaint in pregnancy and may negatively affect quality of life and well being.
The study is designed as an open label, single arm intervention conducted in pregnant women between 13 and 27 weeks of gestation who meet the Cullen 2007 criteria for functional constipation. A total of 31 participants are planned for enrolment. Eligible participants will receive one sachet per day of the Fiber Nutritional Supplement (Materna® Opti fiber), providing approximately 5.8 g of PHGG, for a duration of 4 weeks. In addition to the investigational product, all participants will receive standardized constipation counselling at baseline, including education on constipation, lifestyle measures.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Alison Iroz, PhD
- Número de telefone: +44763720486
- E-mail: alison.petit-jean@nestle.com
Estude backup de contato
- Nome: Irma Silva Zolezzi, PhD
- E-mail: Irma.SilvaZolezzi@nestle.com
Locais de estudo
-
-
São Paulo
-
Osasco, São Paulo, Brasil, 06023-070
- Medcin Pesquisa Clínica
-
Contato:
- Flávia Alvim S. Addor, Profa. Dra.
- Número de telefone: +55 11 94311-7296
- E-mail: contato@medcindermatologia.com.br
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Pregnant women aged 21 years-old or above at recruitment
- Gestational age of 13-27 weeks at recruitment
- Singleton pregnancy at recruitment
Suffering from functional constipation according to the Cullen 2007 criteria which must include ALL the following and the criteria must be fulfilled for at least two weeks with symptom onset during pregnancy:
- Low frequency of stool (<3/week)
- Hard stools
- Difficulty on evacuation
- Able to understand and to sign a written Informed Consent Form (ICF) prior to study enrolment.
- Willing and able to comply with the requirements for participation in this study
- Willing and able to refrain from consuming other supplements containing fiber, prebiotics, or probiotics other than the Fiber Nutritional Supplement (Materna® Opti-fiber) over the intervention period
- Able to respond to questionnaires in English
Exclusion Criteria:
- Treated for constipation less than one week before the start of the study
- Use of prebiotics or probiotics containing supplements two weeks prior to the study start
- Major complications during pregnancy e.g., pre-eclampsia, gestational diabetes requiring insulin intervention, severe intra-uterine growth restriction (IUGR), fetal anomalies that in the opinion of the investigator may interfere with the pregnancy and participation in the clinical trial
- Pre-existing medical conditions e.g., hypertension, diabetes mellitus, thyroid diseases, autoimmune diseases such as Systemic Lupus Erythematosus, antiphospholipid syndrome and other major chronic illness that in the opinion of the investigator may interfere with the pregnancy and participation in the clinical trial
- Not willing and/or not able to comply with the study procedures and requirements
- Known serious food allergy
- Known or suspected history of allergy or intolerance to the investigational product (IP)
- Active participation in another clinical trial or on-going observational study
- Family or hierarchical relationships with the research team members
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Interventional
Fiber Nutritional Supplement with constipation counselling
|
fiber supplement is in powder form and packaged in 6 gram sachets containing approximately 5.8 grams PHGG
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in stool frequency from baseline to 4 weeks of intervention
Prazo: 4 weeks
|
Change in stool frequency from baseline (V1) to 4 weeks of intervention (V2) assessed using a Gut Health Questionnaire to capture transit time and frequency.
|
4 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Stool consistency including presence of diarrhoea
Prazo: 4 weeks
|
Change in stool consistency from baseline (V1) to 4 weeks of intervention (V2) based on a 7-point Bristol Stool Scale (1=Hard, 7= Watery), including self-reported presence of diarrhoea.
|
4 weeks
|
|
Symptoms of constipation
Prazo: 4 weeks
|
percent of participents with self-reported presence of hard/lumpy stool, straining, and/or less than 3 bowel movements per week
|
4 weeks
|
|
Symptoms of gut discomfort
Prazo: 4 weeks
|
Frequencey of self-reported presence of abdominal pain, abdominal discomfort abdominal bloating, gassiness / flatulence), and/or pain during defecation (completed at V2 only following 4 weeks of intervention)
|
4 weeks
|
|
Healthcare and pharmacological utilization
Prazo: 4 weeks
|
Healthcare and pharmacological utilization for issues related to GI health and absenteeism from work for issues related to GI health
|
4 weeks
|
|
Product acceptance
Prazo: 4 weeks
|
Self-reported score rom 1 - 5, where 1 = "Very poor", 5 = "Excellent" on product acceptance and ease of use after 4 weeks of intervention (completed at V2 only) using a questionnaire developed for the study.
|
4 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Flávia SantAnna Addor, MEDCIN PESQUISA CLINICA LTDA
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 26.01NPTC
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .